195rar <TRUSTED>

By changing a specific sequence of amino acids from to GAL , researchers created a mutant version of the protein.

Because this specific interaction is so vital for the cancer to progress, it identified a new potential "weak spot" that future drugs could target to treat AML more effectively. 195rar

Highly active SYK can help cancer cells ignore standard treatments meant to kill FLT3-driven leukemia. By changing a specific sequence of amino acids

SYK must physically touch FLT3 to activate it. SYK must physically touch FLT3 to activate it

In scientific research, "195RAR" refers to a specific genetic mutation used to study how certain proteins interact within the body, particularly in the context of cancer development.

The story of is a technical one, centered on the SYK protein and its role in Acute Myeloid Leukemia (AML) . Researchers used this mutation to unlock a secret about how cancer cells survive and resist treatment. The Mystery of the SYK Protein

When the researchers used the SYK mutant with the change, the protein could no longer bind to FLT3. This was a "Eureka" moment because it proved: